WallStSmart

20/20 Biolabs, Inc. Common Stock (AIDX)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 1137158% more annual revenue ($20.98B vs $1.84M). GEHC leads profitability with a 9.1% profit margin vs -279.1%. GEHC earns a higher WallStSmart Score of 57/100 (C).

AIDX

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 6.3
Piotroski: 3/9

GEHC

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 5.7Quality: 4.5
Piotroski: 2/9Altman Z: 1.34

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AIDX2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

GEHC2 strengths · Avg: 8.0/10
P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Areas to Watch

AIDX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$6.97M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-354.6%2/10

ROE of -354.6% — below average capital efficiency

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.834/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-30.9%2/10

Earnings declined 30.9%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AIDX

The strongest argument for AIDX centers on Debt/Equity, Price/Book.

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio, Price/Book.

Bear Case : AIDX

The primary concerns for AIDX are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

AIDX profiles as a turnaround stock while GEHC is a value play — different risk/reward profiles.

GEHC carries more volatility with a beta of 0.86 — expect wider price swings.

GEHC is growing revenue faster at 7.4% — sustainability is the question.

GEHC generates stronger free cash flow (112M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (57/100 vs 21/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

20/20 Biolabs, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

20/20 Biolabs, Inc. (AIDX) is an innovative biotechnology firm committed to revolutionizing genomic research and diagnostics through its advanced laboratory services. With a keen focus on enhancing the accuracy and efficiency of genetic testing for clinical and research purposes, the company is poised to be a leader in the molecular diagnostics landscape. By leveraging state-of-the-art technologies, 20/20 Biolabs is strategically positioned to capitalize on the growing demand for personalized medicine and genomic data. Its strong market presence and forward-thinking initiatives underscore a compelling growth outlook within the rapidly evolving biotechnology sector.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?